Drug Insights

Is Bempedoic acid approved by the FDA?

27 June 2024
3 min read

Yes, bempedoic acid, marketed under the brand name Nexletol, is FDA approved. The U.S. Food and Drug Administration (FDA) approved bempedoic acid on February 21, 2020. This medication offers a novel approach to lowering cholesterol levels and reducing the risk of heart-related events for adults with certain conditions.

What is Bempedoic Acid?

Bempedoic acid is an oral tablet used to manage high cholesterol levels. It is specifically indicated for:

  • Lowering the risk of heart attack and heart procedures (e.g., stent placement or bypass surgery) in adults with known heart disease or those at high risk for heart disease who are not taking statins.
  • Reducing low-density lipoprotein (LDL) cholesterol in adults with primary hyperlipidemia, including those with heterozygous familial hypercholesterolemia (HeFH).

Bempedoic acid works by inhibiting an enzyme called adenosine triphosphate-citrate lyase (ACL), which plays a crucial role in cholesterol production in the liver.

Usage and Dosage

Bempedoic acid is available as Nexletol, in the form of 180 mg oral tablets. The recommended dosage is one tablet per day, which can be taken with or without food. It is typically used in conjunction with dietary changes and possibly other cholesterol-lowering medications.

Side Effects

While bempedoic acid is generally well tolerated, it can cause some side effects, including:

  • Common cold symptoms
  • Back pain
  • Stomach pain
  • High uric acid levels, which can lead to gout
  • Increased liver enzymes
  • Muscle spasms
  • Anemia
  • Bronchitis

Serious Side Effects

Bempedoic acid may cause serious side effects such as:

  • Increased Uric Acid Levels: This can lead to hyperuricemia and gout. Symptoms include severe foot pain, warm joints, swelling, and redness.
  • Tendon Rupture or Injury: The risk is higher in individuals over 60, those taking corticosteroids or fluoroquinolones, and those with renal failure or previous tendon issues. Symptoms include pain, swelling, and difficulty moving the affected area.

Warnings and Precautions

Before taking bempedoic acid, it is essential to inform your healthcare provider of any medical conditions, especially if you have a history of gout, tendon problems, severe kidney or liver issues, or if you are pregnant or breastfeeding.

Conclusion

Bempedoic acid (Nexletol) is a valuable FDA-approved option for individuals needing additional cholesterol management and risk reduction for heart disease, especially for those who are unable to take statins. Approved on February 21, 2020, it provides an effective solution for lowering LDL cholesterol levels and helping to prevent heart attacks and other heart procedures.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Mim8 Outperforms On-Demand Treatments in Haemophilia A Patients
Latest Hotspot
3 min read
Mim8 Outperforms On-Demand Treatments in Haemophilia A Patients
27 June 2024
Novo Nordisk A/S: Mim8 showed better reductions in annual bleeding rates (ABR) than on-demand treatments and previous prophylaxis in haemophilia A patients.
Read →
Is Eptinezumab approved by the FDA?
Drug Insights
3 min read
Is Eptinezumab approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved Eptinezumab on February 21, 2020.
Read →
DA-1726 Outperforms Survodutide in Pre-Clinical Weight Reduction and Health Metrics
Latest Hotspot
3 min read
DA-1726 Outperforms Survodutide in Pre-Clinical Weight Reduction and Health Metrics
27 June 2024
In pre-clinical models, DA-1726 from NeuroBo Pharmaceuticals outperformed Survodutide in weight reduction, maintaining lean body mass, and lowering lipid levels.
Read →
Is Palforzia approved by the FDA?
Drug Insights
3 min read
Is Palforzia approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved Palforzia on January 31, 2020.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.